Section Arrow
Quote
GH.NASDAQ
- Guardant Health
Quotes are at least 15-min delayed:2026/02/12 08:06 EST
Pre Market
Last
 107.58
0 (0.00%)
Bid
102
Ask
109
High 108.22 
Low 107.49 
Volume 41 
Regular Hours (Closed)
Last
 107.58
+2.55 (+2.43%)
Day High 
107.6709 
Prev. Close
105.03 
1-M High
120.74 
Volume 
1.76M 
Bid
102
Ask
109
Day Low
100.26 
Open
106.3 
1-M Low
97.52 
Market Cap 
13.64B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 107.89 
20-SMA 110.53 
50-SMA 106.41 
52-W High 120.74 
52-W Low 34.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.22/-1.38
Enterprise Value
14.95B
Balance Sheet
Book Value Per Share
-2.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
739.02M
Operating Revenue Per Share
4.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IQVIQVIA Holdings177.18-5.27-2.89%24.37PE
Pre Market 165 -12.18 -6.87%
DHRDanaher Corp219.98+0.23+0.10%45.39PE
Pre Market 219.61 -0.37 -0.17%
WATWaters Corp329.2+2.18+0.67%30.26PE
Pre Market 331.555 +2.355 +0.72%
NEOGNeogen Corp10.75+0.02+0.19%-- 
Pre Market 10.66 -0.09 -0.84%
ICLRICON plc133.14-11.41-7.89%17.94PE
Pre Market 93.15 -39.99 -30.04%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.